Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.46−1.23 (-2.69%)
Close on Nov 13, 2026Market cap $830.51MP/E 2.9Yield –
Rigel Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Rigel Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 26.3%. For fiscal 2025 it was 42.6%, against 13.5% the year before. The highest annual figure on record is 42.6% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.6% | +29.1 |
| FY2024 | Dec 31, 2024 | 13.5% | +31.0 |
| FY2023 | Dec 31, 2023 | -17.5% | +28.7 |
| FY2022 | Dec 31, 2022 | -46.2% | −37.8 |
| FY2021 | Dec 31, 2021 | -8.4% | +18.3 |
| FY2020 | Dec 31, 2020 | -26.7% | +89.9 |
| FY2019 | Dec 31, 2019 | -116.5% | +46.8 |
| FY2018 | Dec 31, 2018 | -163.3% | +1612.3 |
| FY2017 | Dec 31, 2017 | -1775.6% | −1433.4 |
| FY2016 | Dec 31, 2016 | -342.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 21.1% | −19.8 |
| Q2 FY2026 | Jun 30, 2026 | 30.0% | −30.1 |
| Q1 FY2026 | Mar 31, 2026 | 20.2% | −3.7 |
| Q4 FY2025 | Dec 31, 2025 | 33.2% | +4.3 |
| Q3 FY2025 | Sep 30, 2025 | 40.9% | +15.5 |
| Q2 FY2025 | Jun 30, 2025 | 60.1% | +58.9 |
| Q1 FY2025 | Mar 31, 2025 | 23.9% | +47.5 |
| Q4 FY2024 | Dec 31, 2024 | 28.9% | +23.4 |
| Q3 FY2024 | Sep 30, 2024 | 25.4% | +41.3 |
| Q2 FY2024 | Jun 30, 2024 | 1.2% | +20.8 |
| Q1 FY2024 | Mar 31, 2024 | -23.6% | +25.2 |
| Q4 FY2023 | Dec 31, 2023 | 5.5% | +1.4 |
| Q3 FY2023 | Sep 30, 2023 | -15.9% | +66.2 |
| Q2 FY2023 | Jun 30, 2023 | -19.6% | +23.9 |
| Q1 FY2023 | Mar 31, 2023 | -48.8% | +108.1 |
| Q4 FY2022 | Dec 31, 2022 | 4.1% | +109.0 |
| Q3 FY2022 | Sep 30, 2022 | -82.1% | +9.7 |
| Q2 FY2022 | Jun 30, 2022 | -43.5% | +6.2 |
| Q1 FY2022 | Mar 31, 2022 | -156.9% | −208.5 |
| Q4 FY2021 | Dec 31, 2021 | -104.9% | −2.9 |
| Q3 FY2021 | Sep 30, 2021 | -91.8% | −16.9 |
| Q2 FY2021 | Jun 30, 2021 | -49.7% | +58.9 |
| Q1 FY2021 | Mar 31, 2021 | 51.5% | +13.8 |
| Q4 FY2020 | Dec 31, 2020 | -102.0% | +10.5 |
| Q3 FY2020 | Sep 30, 2020 | -74.9% | −17.2 |
| Q2 FY2020 | Jun 30, 2020 | -108.6% | +96.5 |
| Q1 FY2020 | Mar 31, 2020 | 37.7% | +183.3 |
| Q4 FY2019 | Dec 31, 2019 | -112.6% | −119.3 |
| Q3 FY2019 | Sep 30, 2019 | -57.7% | +443.2 |
| Q2 FY2019 | Jun 30, 2019 | -205.0% | +1256.1 |
| Q1 FY2019 | Mar 31, 2019 | -145.6% | +1838.3 |
| Q4 FY2018 | Dec 31, 2018 | 6.7% | +458.8 |
| Q3 FY2018 | Sep 30, 2018 | -500.9% | – |
| Q2 FY2018 | Jun 30, 2018 | -1461.2% | – |
| Q3 FY2017 | Sep 30, 2017 | -1983.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -452.1% | – |
See a number that looks wrong?